Neurology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study.
Current evidence-based acute treatments of cluster headache are limited to oxygen inhalation and subcutaneous sumatriptan. Intranasal sumatriptan is a new formulation with better tolerability than the subcutaneous route. Two open-label studies suggested efficacy of intranasal sumatriptan in cluster headache. ⋯ Sumatriptan nasal spray is effective and well tolerated in the acute treatment of cluster headache attacks of at least 45 minutes' duration.
-
Clinical Trial Controlled Clinical Trial
Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy.
To differentiate the quantitative sensory testing (QST) results of subjects simulating small and large fiber sensory loss from those of normal subjects and subjects with sensory peripheral neuropathy. ⋯ Test performance characteristics do not permit discrimination among subjects simulating sensory loss, subjects with normal responses, and subjects with peripheral neuropathy.
-
Clinical Trial Controlled Clinical Trial
Atrophy rates of entorhinal cortex in AD and normal aging.
To explore the atrophy rate of entorhinal cortex (ERC) in AD and normal aging and assess the value of rate measurement of ERC atrophy for classifying subjects with AD from cognitively normal (CN) control subjects. ⋯ ERC volume loss over time may be a better indicator for AD than cross-sectional measurements.
-
To assess the incidence and predictive factors of early and late seizures after ischemic stroke in young adults. ⋯ Epilepsy is rarely a major problem in young cryptogenic ischemic stroke survivors. Early seizures are associated with stroke disability and cortical involvement. Early seizures, cortical signs, and large infarct are independent risk factors for late seizures.
-
Practice Guideline Guideline
Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society.
To make evidence-based recommendations concerning the evaluation of the child with a nonprogressive global developmental delay. ⋯ A specific etiology can be determined in the majority of children with global developmental delay. Certain routine screening tests are indicated and depending on history and examination findings, additional specific testing may be performed.